Patients are suffering now since Health Insurance Review & Assessment Service and Pfizer are at tug-of-war over the insurance benefit

Non-small cell lung cancer(NSCLC) drug, Xalkori, is now on the issue of being insurance benefit. NSCLC patients are suffering from a tug-of-war between HIRA and Pfizer.

Not only Pfizer, HIRA also recognizes the need for benefits. However, last November, HIRA made a decision on Xalkori as non-insurance benefit. Pfizer required HIRA to allow the drug as insurance benefit last July, but they fail...